Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
55M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
43.9M
-
Shares change
-
-2.54M
-
Total reported value, excl. options
-
$173M
-
Value change
-
-$18.2M
-
Put/Call ratio
-
0.39
-
Number of buys
-
41
-
Number of sells
-
-54
-
Price
-
$3.94
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q3 2023
121 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2023.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.9M shares
of 55M outstanding shares and own 79.86% of the company stock.
Largest 10 shareholders include Skorpios Trust (14.4M shares), RTW INVESTMENTS, LP (4.39M shares), Redmile Group, LLC (3.87M shares), COWEN AND COMPANY, LLC (3.72M shares), MORGAN STANLEY (2.91M shares), BlackRock Inc. (2.21M shares), Lynx1 Capital Management LP (1.71M shares), VANGUARD GROUP INC (1.63M shares), BAKER BROS. ADVISORS LP (1.49M shares), and Cormorant Asset Management, LP (1.09M shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.